Gemcitabine + Abraxane - Standard for Pancreatic Cancer | Investigational Agents - Nivolumab-Anti-PD1 & Anti-CD40

Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the combination of Gemcitabine + Abraxane - Standard for Pancreatic Cancer | Investigational Agents - Nivolumab-Anti-PD1 & Anti... Author: Cancer-News Added: 07/26/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts